- "'Special K': The Science & Stigma of Ketamine" on CNN,
hosted by Dr. Sanjay Gupta
- David Feifel MD PHD, Founder of
Kadima, is a global thought leader in the interventional psychiatry
field
- Kadima Neuropsychiatry Institute identified as planned HOPE
Flagship Clinic pending acquisition closing
- Dr. Feifel is expected to join HOPE as Chief Medical Innovation
Officer
MIAMI, Jan. 14,
2025 /PRNewswire/ -- HOPE Therapeutics™, Inc.,
("HOPE"), a medical and technology driven company, and a
wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and
collectively with HOPE, the "Company") (Nasdaq:NRXP), today alerted
investors that Kadima Neuropsychiatry Institute's Founder
David Feifel, MD PHD was featured as
an expert in a program on ketamine entitled "'Special K': The
Science & Stigma of Ketamine" on CNN, hosted by Dr.
Sanjay Gupta. HOPE previously
announced that Kadima is identified as the Company's planned
flagship clinic acquisition, upon closing of the transaction.
Dr. Feifel, a global leader in interventional psychiatry, has
accepted a future role as Chief Medical Innovation Officer in
conjunction with the previously announced planned acquisition of
Kadima by HOPE. The acquisition is subject to completion of
financial audits and standard closing conditions.
In his comments, Dr. Feifel supported use the of ketamine in
appropriate patients but emphasized the need for appropriate
psychiatric supervision in a controlled setting - a view that HOPE
wholeheartedly shares. This appearance with Dr. Gupta follows his
appearance on another of Dr. Gupta's programs, "The Wild West
of Ketamine Treatment" in August of last year.
"The recent, tragic death of Mathew
Perry underscores the need for people with depression to
have access to psychiatric centers of excellence where they can
receive ketamine and other advanced treatments at the highest
standard of medical care," said David
Feifel. "I plan to bring this same vision for use of
ketamine and other interventional psychiatry treatment methods that
made my clinic, Kadima, an industry gold-standard, to the HOPE
network, upon joining the Company."
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc.
(www.hopetherapeutics.com) is a development stage healthcare
delivery company that intends to develop a best-in-class network of
interventional psychiatry clinics to offer ketamine
transcranial magnetic stimulation (TMS) and other lifesaving
therapies to patients with suicidal depression and related
disorders, together with a digital therapeutic-enabled platform
designed to augment and preserve the clinical benefit of
NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is
a clinical-stage biopharmaceutical company developing therapeutics
based on its NMDA platform for the treatment of central nervous
system disorders, specifically suicidal bipolar depression, chronic
pain, and PTSD. The Company is developing NRX-101, an
FDA-designated investigational Breakthrough Therapy for suicidal
treatment-resistant bipolar depression and chronic pain. NRx plans
to file an NDA for Accelerated Approval for NRX-101 in patients
with bipolar depression and suicidality or akathisia. NRX-101
additionally has potential to act as a non-opioid treatment for
chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced initiation of filing a New Drug
Application for NRX-100 (IV ketamine) for the treatment of suicidal
depression, based on results of well-controlled clinical trials
conducted under the auspices of the US National Institutes of
Health and newly obtained data from French health authorities,
licensed under a data sharing agreement. NRx was awarded Fast Track
Designation for development of ketamine (NRX-100) by the US FDA as
part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The
information contained herein includes forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of
1934, as amended, and Section 27A of the Securities Act of 1933, as
amended. These statements include, among others, statements
regarding closing the acquisition of Kadima and obtaining financing
necessary to consummate the acquisition. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as "may," "will," "should," "would," "expect," "plan,"
"believe," "intend," "look forward," and other similar expressions
among others. These statements relate to future events or to the
Company's future financial performance, and involve known and
unknown risks, uncertainties and other factors that may cause the
Company's actual results to be materially different from any future
results, levels of activity, performance or achievements expressed
or implied by these forward-looking statements. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. Any forward-looking
statement reflects the Company's current views with respect to
future events and is subject to these and other risks,
uncertainties and assumptions relating to the Company's operations,
results of operations, growth strategy, liquidity, Hope
Therapeutic's ability to consummate the acquisitions of providers
for its national network, the Company's ability to raise adequate
capital to fund the Hope Therapeutics acquisitions, and the
Company's ability to spin-off Hope Therapeutics. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company's most recent Annual Report on Form 10-K and other filings
with the Securities and Exchange Commission. Investors and security
holders are urged to read these documents free of charge on the
SEC's website at http://www.sec.gov. Except as may be required
by applicable law, The Company assumes no obligation to publicly
update or revise these forward-looking statements for any reason,
or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, whether
as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE
Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-alert-investors-to-sanjay-guptacnn-program-on-ketamine-featuring-kadima-neuropsychiatry-institute-founder-dr-david-feifel-302350245.html
SOURCE NRx Pharmaceuticals, Inc.
